Literature DB >> 22955441

Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic.

Molebogeng X Rangaka1, Robert J Wilkinson, Judith R Glynn, Andrew Boulle, Gilles van Cutsem, Rene Goliath, Shaheed Mathee, Gary Maartens.   

Abstract

BACKGROUND: Current symptom screening algorithms for intensified tuberculosis case finding or prior to isoniazid preventive therapy (IPT) in patients infected with human immunodeficiency virus (HIV) were derived from antiretroviral-naive cohorts. There is a need to validate screening algorithms in patients on antiretroviral therapy (ART).
METHODS: We performed cross-sectional evaluation of the diagnostic accuracy of symptom screening, including the World Health Organization (WHO) algorithm, to rule out tuberculosis in HIV-infected individuals pre-ART and on ART undergoing screening prior to IPT.
RESULTS: A total of 1429 participants, 54% on ART, had symptom screening and a sputum culture result available. Culture-positive tuberculosis was diagnosed in 126 patients (8.8%, 95% confidence interval [CI], 7.4%-10.4%). The WHO symptom screen in the on-ART compared with the pre-ART group had a lower sensitivity (23.8% vs 47.6%), but higher specificity (94.4% vs 79.8%). The effect of ART was independent of CD4(+) count in multivariable analyses. The posttest probability of tuberculosis following a negative WHO screen was 8.9% (95% CI, 7.4%-10.8%) and 4.4% (95% CI, 3.7%-5.2%) for the pre-ART and on-ART groups, respectively. Addition of body mass index to the WHO screen significantly improved discriminatory ability in both ART groups, which was further improved by adding CD4 count and ART duration.
CONCLUSIONS: The WHO symptom screen has poor sensitivity, especially among patients on ART, in a clinic where regular tuberculosis screening is practiced. Consequently, a significant proportion of individuals with tuberculosis would inadvertently be placed on isoniazid monotherapy despite high negative predictive values. Until more sensitive methods of ruling out tuberculosis are established, it would be prudent to do a sputum culture prior to IPT where this is feasible.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22955441      PMCID: PMC3501332          DOI: 10.1093/cid/cis775

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  25 in total

1.  Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing.

Authors:  David W Dowdy; Richard E Chaisson; Gary Maartens; Elizabeth L Corbett; Susan E Dorman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-11       Impact factor: 11.205

2.  Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation.

Authors:  Stephen D Lawn; Landon Myer; Guy Harling; Catherine Orrell; Linda-Gail Bekker; Robin Wood
Journal:  Clin Infect Dis       Date:  2006-08-08       Impact factor: 9.079

Review 3.  Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa.

Authors:  Stephen D Lawn; Anthony D Harries; Xavier Anglaret; Landon Myer; Robin Wood
Journal:  AIDS       Date:  2008-10-01       Impact factor: 4.177

4.  Intensified tuberculosis case finding among HIV-Infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia.

Authors:  Sarita Shah; Meaza Demissie; Lauren Lambert; Jelaludin Ahmed; Sileshi Leulseged; Tekeste Kebede; Zenebe Melaku; Yohannes Mengistu; Eshetu Lemma; Charles D Wells; Tadesse Wuhib; Lisa J Nelson
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-15       Impact factor: 3.731

5.  Screening for tuberculosis in adults with advanced HIV infection prior to preventive therapy.

Authors:  A Mohammed; R Ehrlich; R Wood; F Cilliers; G Maartens
Journal:  Int J Tuberc Lung Dis       Date:  2004-06       Impact factor: 2.373

6.  Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1995

7.  Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda.

Authors:  David Moore; Cheryl Liechty; Paul Ekwaru; Willy Were; Gerald Mwima; Peter Solberg; George Rutherford; Jonathan Mermin
Journal:  AIDS       Date:  2007-03-30       Impact factor: 4.177

8.  Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa.

Authors:  J H Day; S Charalambous; K L Fielding; R J Hayes; G J Churchyard; A D Grant
Journal:  Int J Tuberc Lung Dis       Date:  2006-05       Impact factor: 2.373

9.  Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease.

Authors:  Elizabeth L Corbett; Tsitsi Bandason; Yin Bun Cheung; Shungu Munyati; Peter Godfrey-Faussett; Richard Hayes; Gavin Churchyard; Anthony Butterworth; Peter Mason
Journal:  PLoS Med       Date:  2007-01       Impact factor: 11.069

10.  Pulmonary tuberculosis among people living with HIV/AIDS attending care and treatment in rural northern Tanzania.

Authors:  Bernard J Ngowi; Sayoki G Mfinanga; Johan N Bruun; Odd Morkve
Journal:  BMC Public Health       Date:  2008-09-30       Impact factor: 3.295

View more
  29 in total

1.  Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped.

Authors:  Faiz Ahmad Khan; Sabine Verkuijl; Andrew Parrish; Fadzai Chikwava; Raphael Ntumy; Wafaa El-Sadr; Andrea A Howard
Journal:  AIDS       Date:  2014-06-19       Impact factor: 4.177

2.  Symptom screening for active tuberculosis in pregnant women living with HIV.

Authors:  Sylvia M LaCourse; Lisa M Cranmer; Adrie Bekker; Karen R Steingart; Danae Black; David J Horne; Eyal Oren; Sherri Pals; Surbhi Modi; Jyoti Mathad
Journal:  Cochrane Database Syst Rev       Date:  2018-01-24

Review 3.  Diagnostic point-of-care tests in resource-limited settings.

Authors:  Paul K Drain; Emily P Hyle; Farzad Noubary; Kenneth A Freedberg; Douglas Wilson; William R Bishai; William Rodriguez; Ingrid V Bassett
Journal:  Lancet Infect Dis       Date:  2013-12-10       Impact factor: 25.071

Review 4.  Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.

Authors:  Paul K Drain; Kristina L Bajema; David Dowdy; Keertan Dheda; Kogieleum Naidoo; Samuel G Schumacher; Shuyi Ma; Erin Meermeier; David M Lewinsohn; David R Sherman
Journal:  Clin Microbiol Rev       Date:  2018-07-18       Impact factor: 26.132

5.  Integrating tuberculosis screening in Kenyan Prevention of Mother-To-Child Transmission programs.

Authors:  L M Cranmer; A Langat; K Ronen; C J McGrath; S LaCourse; J Pintye; B Odeny; B Singa; A Katana; L Nganga; J Kinuthia; G John-Stewart
Journal:  Int J Tuberc Lung Dis       Date:  2017-03-01       Impact factor: 2.373

6.  Tuberculosis Case Finding in HIV-Infected Pregnant Women in Kenya Reveals Poor Performance of Symptom Screening and Rapid Diagnostic Tests.

Authors:  Sylvia M LaCourse; Lisa M Cranmer; Daniel Matemo; John Kinuthia; Barbra A Richardson; Grace John-Stewart; David J Horne
Journal:  J Acquir Immune Defic Syndr       Date:  2016-02-01       Impact factor: 3.731

7.  Diagnostic and Prognostic Value of Serum Albumin for Tuberculosis in HIV Infected Patients Eligible for Antiretroviral Therapy: Datafrom an HIV Cohort Study in India.

Authors:  Gerardo Alvarez-Uria; Manoranjan Midde; Raghavakalyan Pakam; Praveen Kumar Naik
Journal:  Bioimpacts       Date:  2013-09-01

8.  Tuberculosis preventive treatment opportunities at antiretroviral therapy initiation and follow-up visits.

Authors:  T Agizew; D Surie; J E Oeltmann; M Letebele; S Pals; U Mathebula; A Mathoma; M Kassa; S Hamda; P Pono; G Rankgoane-Pono; R Boyd; A Auld; A Finlay
Journal:  Public Health Action       Date:  2020-06-21

9.  Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.

Authors:  Molebogeng X Rangaka; Robert J Wilkinson; Andrew Boulle; Judith R Glynn; Katherine Fielding; Gilles van Cutsem; Katalin A Wilkinson; Rene Goliath; Shaheed Mathee; Eric Goemaere; Gary Maartens
Journal:  Lancet       Date:  2014-05-13       Impact factor: 79.321

Review 10.  Cough Due to TB and Other Chronic Infections: CHEST Guideline and Expert Panel Report.

Authors:  Stephen K Field; Patricio Escalante; Dina A Fisher; Belinda Ireland; Richard S Irwin
Journal:  Chest       Date:  2017-11-28       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.